WuXi PharmaTech, China's largest CRO, is blueprinting forays into two of the hottest locales for U.S. R&D, planning to open offices in Boston and San Francisco.
PPD has signed a data-minded deal with the collection experts at ERT, a partnership the companies believe will help their clients conduct more efficient trials.
Health Decisions, a week removed from the plane crash that claimed the life of its CEO, has recruited a CRO veteran from the University of North Carolina to step in as interim chief executive and oversee its transition.
BioClinica, fresh from its latest merger, has named a Pfizer executive as its next CEO.
North Carolina CRO Health Decisions is working its way back to normalcy after the death of its founder and CEO, processing a loss that "devastated" its staff, an executive said.
Covance got some bad advice when it agreed to a roughly $6 billion buyout from LabCorp, according to an investor lawsuit, which alleges that chief dealbroker Goldman Sachs had a conflict of interest all along.
Kidney dialysis magnate DaVita HealthCare Partners has merged its two research-minded subsidiaries to create an end-to-end CRO focused on renal trials.
Clinical trial tech outfit Medidata is expanding its work in risk-based monitoring, buying a startup called Patient Profiles to help sponsors and CROs use real-time safety data to make decisions on studies.
X-Chem, PPD's in-house biotech company, has signed a deal with the rare disease specialists at Alexion to lend out its molecular library and help discover new treatments.
INC Research has deepened its partnership with the Society for Clinical Research Sites, supporting a training program and working to increase communication between trial sites and study investigators.
Catalent has signed a deal with Sellas to help the Swiss drugmaker develop an existing insomnia treatment for other central nervous system disorders.
Meda, a Swedish specialty pharma outfit, is scaling back its relationship with contract drug developer Recipharm, endangering jobs and putting a site at risk of closure.
WuXi PharmaTech is moving toward an IPO for one of its R&D and manufacturing subsidiaries, hoping to take advantage of a new market in its native China.
Some European Union states have suspended the approvals of drugs tied to a data falsification scandal at CRO GVK Biosciences, and the European Medicines Agency is investigating whether to recommend a continental halt.
Quintiles has unveiled a new offering that combines its pharmacovigilance, label management, risk-benefit research and analytics into a single product, touting the service as a catch-all for approved drugs.
Indian CRO GVK Biosciences has signed a deal with a Japanese outfit to market its drug repurposing services in the country, part of the company's plot to diversify its revenue sources.
WuXi PharmaTech has spent the last year and change amping up its genomics expertise, and now China's largest CRO has signed a deal with Cambridge, MA's NextCODE Health to further grow its bioinformatics offerings.
Pharma outsourcer Almac has signed a deal that allows it to add emergency services to its clinical trial management platform, allowing sponsors to quickly handle unforeseen problems and minimize the need for unblinding data, the company said.
Fast-growing German CRO Accovion has made its way into France, opening up a new subsidiary as it works to become Europe's biggest independent pharma outsourcer.
Swedish contract drug developer Recipharm has signed a deal to extend its reach into France, buying a new facility and partnering with a local firm.